UPDATE: Goldman Sachs Initiates Zoetis at Neutral; Upside Limited From Current Valuation
Goldman Sachs initiated coverage on Zoetis (NYSE: ZTS) with an Overweight rating and a $33.00 price target.
Goldman Sachs analyst Jami Rubin noted, "ZTS is the largest and only independently traded animal health company, with revenues of over $4.0 bn. We anticipate powerful macro trends in livestock and companion animals to provide tailwinds for sustained top line growth in the 5-7% range, with margin expansion yielding earnings growth in the upper teens through 2014, and low double-digit/high single-digit EPS growth thereafter. As a pure play animal health business, ZTS represents a scarce asset within our healthcare universe; however, as the stock currently trades at 23.5x 2013E we see limited upside from here."
Zoetis closed at $33.82 on Tuesday.
Latest Ratings for ZTS
|Sep 2016||Bank of America||Initiates Coverage on||Buy|
|Sep 2016||Argus Research||Maintains||Below Average|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.